Tag Archives: European Medicines Agency

Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)

Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Quick Insights | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

New Cancer Drugs Often Bestow Little Benefit Regarding Survival or Wellbeing? (NHS Choices / BMJ)

Summary A quotation from the authors’ abstract may say it all: “This systematic evaluation of oncology approvals by the European Medicines Agency (EMA) in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality … Continue reading

Posted in Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, International, Management of Condition, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Statistics, Systematic Reviews, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)

Summary The Medicines and Healthcare Products Regulatory Agency (MHRA) took part in an international workshop with other regulators, and has released a statement of intent about how to support the development of drugs for dementia. This work is in support … Continue reading

Posted in Department of Health, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, World Health Organization (WHO) | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment